Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Sponsor: Neurocrine Biosciences
Summary
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
Official title: A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2025-04-16
Completion Date
2030-05
Last Updated
2025-08-01
Healthy Volunteers
No
Conditions
Interventions
NBI-1065845
NBI-1065845 tablets
Locations (18)
Neurocrine Clinical Site
Little Rock, Arkansas, United States
Neurocrine Clinical Site
Orange, California, United States
Neurocrine Clinical Site
Pico Rivera, California, United States
Neurocrine Clinical Site
Upland, California, United States
Neurocrine Clinical Site
Hollywood, Florida, United States
Neurocrine Clinical Site
Maitland, Florida, United States
Neurocrine Clinical Site
Tampa, Florida, United States
Neurocrine Clinical Site
Atlanta, Georgia, United States
Neurocrine Clinical Site
Boston, Massachusetts, United States
Neurocrine Clinical Site
Watertown, Massachusetts, United States
Neurocrine Clinical Site
Saint Charles, Missouri, United States
Neurocrine Clinical Site
Mount Kisco, New York, United States
Neurocrine Clinical Site
The Bronx, New York, United States
Neurocrine Clinical Site
Avon Lake, Ohio, United States
Neurocrine Clinical Site
Dallas, Texas, United States
Neurocrine Clinical Site
Richmond, Texas, United States
Neurocrine Clinical Site
The Woodlands, Texas, United States
Neurocrine Clinical Site
Everett, Washington, United States